US 12,168,687 B2
Antibodies to programmed cell death protein 1 that are PD-1 agonists
Mikayel Mkrtichyan, Tujunga, CA (US); and Samir Khleif, Bethesda, MD (US)
Assigned to Georgiamune Inc., Gaithersburg, MD (US)
Filed by Georgiamune Inc., Gaithersburg, MD (US)
Filed on Jan. 26, 2024, as Appl. No. 18/423,752.
Application 18/423,752 is a continuation of application No. PCT/US2023/061449, filed on Jan. 27, 2023.
Claims priority of provisional application 63/304,365, filed on Jan. 28, 2022.
Prior Publication US 2024/0182574 A1, Jun. 6, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01); C07K 2317/75 (2013.01)] 30 Claims
 
1. An antibody or antigen-binding fragment thereof having binding specificity for programmed cell death receptor protein 1 (PD-1) comprising a light chain variable region and a heavy chain variable region, wherein the antibody or antigen-binding fragment comprises: CDR L1 comprising SEQ ID NO:114, CDR L2 comprising KVS, CDR L3 comprising SEQ ID NO:134, CDR H1 comprising SEQ ID NO:32, CDR H2 comprising SEQ ID NO:53, and CDR H3 comprising SEQ ID NO:74.